tremelimumab,durvalumab
astrazeneca,pfizer
['gastric', 'prodige 59', '1204mo', 'durva', 'durigast']
 prodige 59 - durigast trial at 1204mo folfiri + durva vs folfiri + durva/treme in 2nd line gej/gc, 96 its mpfs 3.8 vs 5.4mo, orr 32.6% vs 37.7%, mos 13.3 vs 9.5mo, 1-yr os 15.2% for fdt is there a role for ici in 2nd line? #gastriccancer 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine